Skip to NavigationSkip to content


Hanmi terminates lung cancer drug after being muscled out by AZ's Tagrisso

South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it admits that circumstances within the space have meant that continued R&D costs would “eclipse its value”.

“We found it difficult to find participants for our clinical studies because there is a medication that has already completed global phase 3 trials and is covered by insurance,” a spokesperson for the company said.

Lilly dumps Hanmi’s rheumatoid arthritis med

Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of various autoimmune and other diseases in 2015.

The deal was worth a potential $690 million in total but that hasn’t stopped Lilly showing every sign of ducking out of the deal early.

Janssen buys licence to diabetes and obesity drugs from Hanmi

Janssen image

Janssen could spend up to a billion dollars to buy for novel clinical stage biologics to treat diabetes and obesity.

The firm has obtained the worldwide global license and development rights to develop and commercialise oxyntomodulin-based therapies including HM12525A, a biologic that is completing Phase I clinical trials and which is expected to enter Phase II studies next year from Hanmi Pharmaceutical. The deal, which is potentially worth up to $915 million, will boost Janssen's metabolism portfolio.

Sanofi and Hanmi partner to create long-acting diabetes treatments

Pascale Witz Sanofi
Sanofi's Pascale Witz says the deal demonstrates the company's commitment to diabetes

Sanofi and Hanmi Pharmaceutical have announced a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.

Korea’s Hanmi will receive an upfront payment of €400 million and is eligible for up to €3.5 billion in further payments if it meets milestones in the development, registration and sales of the potential drugs to come out of the partnership.

Lilly and Hanmi enter immunological therapy pact

Lilly image

Eli Lilly and Korean-based pharma firm Hanmi have entered a collaboration agreement to develop and commercialise an immunological therapy.

The oral bruton tyrosine kinase (BTK) inhibitor HM71224, is ready to enter Phase II trials to investigate the molecule for treatment of rheumatoid arthritis, lupus and Sjögren's syndrome – a chronic disease in which the body's white blood cells destroy the exocrine glands.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches